RxDoctor Payments Data

Raymond Chan, MD

Ophthalmology · San Diego, CANPI 1730298373

Payments from drug & device makers

$40,959in general payments, 2019–2025

Across 216 payments — averaging $189.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • Sun Pharmaceutical Industries Inc.$15K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$6K
  • Bausch & Lomb Americas Inc.$1K
  • Shire North American Group Inc$271
  • Aerie Pharmaceuticals, Inc.$107
  • plus $26 from 1 others

What the payments were for

  • Speaking & faculty fees$34,59084%
  • Travel & lodging$1,1133%
  • Food & beverage$5,25613%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,959 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$95,156
Medicare patients
84
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod240$105,951
CequaCyclosporine131$93,474
ProlensaBromfenac Sodium124$72,319
MieboPerfluorohexyloctane/Pf60$45,395
ZyletTobramycin/Lotepred Etab14$14,214
Lotemax SmLoteprednol Etabonate25$12,850
AzoptBrinzolamide24$10,896
Bepotastine Besilate29$9,067
CombiganBrimonidine Tartrate/Timolol27$6,775
Brinzolamide34$6,061
Timolol Maleate27$4,616
LotemaxLoteprednol Etabonate12$3,926
Alphagan PBrimonidine Tartrate14$3,591
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta, Miebo$1,072$151,346300 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Zylet, Lotemax Sm, Lotemax$6,002$103,308175 claims
Sun Pharmaceutical Industries Inc.Cequa$15,259$93,474131 claims
AbbVieCombigan, Alphagan P$18,222$10,36541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →